Cargando…

Qishen Yiqi dropping pills improve isoproterenol-induced cardiomyocyte hypertrophy by regulating X-inactive specific transcript (XIST) expression in rats

BACKGROUND: This study aimed to explore the potential mechanism of Qishen Yiqi dropping pills (QYDPs) in the treatment of chronic heart failure (CHF) by regulating the expression of lncRNAs during CHF. METHODS: Differences in the expression of the long non-coding RNA (lncRNA), X-inactive specific tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Ying, Chen, Jiaxian, Chen, Yuewu, Su, Yangshen, Wu, Xiaoyan, Zheng, Wanling, Liu, Xianxia, Chen, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264057/ https://www.ncbi.nlm.nih.gov/pubmed/35813728 http://dx.doi.org/10.21037/jtd-22-606

Ejemplares similares

Qishen Yiqi dropping pills improve cardiomyocyte hypertrophy via the lncRNA TINCR/miR-193b-3p/RORA axis
por: Chen, Lei, et al.
Publicado: (2022)

Qishen Yiqi Drop Pill improves cardiac function after myocardial ischemia
por: JianXin, Chen, et al.
Publicado: (2016)

Antiplatelet Effects of Qishen Yiqi Dropping Pill in Platelets Aggregation in Hyperlipidemic Rabbits
por: Wang, Yi, et al.
Publicado: (2012)

Protective effect of Qishen Yiqi dropping pills on the myocardium of rats with chronic heart failure
por: Lu, Yinghong, et al.
Publicado: (2019)

Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose‐induced injury in cardiomyocytes
por: Zhang, Shouyan, et al.
Publicado: (2019)

Qishen Yiqi Dropping Pills Ameliorates Doxorubicin-Induced Cardiotoxicity in Mice via Enhancement of Cardiac Angiogenesis
por: Wang, Lijiang, et al.
Publicado: (2019)

Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies
por: Wang, Hao, et al.
Publicado: (2020)

The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses
por: Chen, Wensheng, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Qishen Yiqi Dropping Pill Combined with Conventional Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis
por: Chen, Lisheng, et al.
Publicado: (2021)

Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT‐IHF randomized clinical trial
por: Mao, Jingyuan, et al.
Publicado: (2020)

Qishen Yiqi dripping pills for ischemic heart failure: A protocol for a prospective cohort study
por: Zhao, Zhiqiang, et al.
Publicado: (2018)

Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
por: Wang, Mengxi, et al.
Publicado: (2021)

The Mechanism Research of Qishen Yiqi Formula by Module-Network Analysis
por: Zheng, Shichao, et al.
Publicado: (2015)

Qishen Yiqi Dripping Pill Protects Diabetic Nephropathy by Inhibiting the PI3K-AKT Signaling Pathways in Rats
por: Li, Shaohua, et al.
Publicado: (2022)

Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure: A protocol of updated systematic review and meta-analysis
por: Guan, Hui, et al.
Publicado: (2021)

Qishen Yiqi Dripping Pill Protects Against Diabetic Nephropathy by Inhibiting the Wnt/β-Catenin and Transforming Growth Factor-β/Smad Signaling Pathways in Rats
por: Zhang, Qian, et al.
Publicado: (2021)

A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Effect of Qishen Yiqi Dripping Pills on Exercise Endurance and Quality of Life in Patients with Coronary Heart Disease after Percutaneous Coronary Intervention
por: Yu, Linghua, et al.
Publicado: (2021)

QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology
por: Li, Meng, et al.
Publicado: (2022)

Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF)
por: Hou, Ya Zhu, et al.
Publicado: (2013)

Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro
por: Qi, Jianyong, et al.
Publicado: (2017)

Effects of Yiqi Huoxue Decoction on Post-Myocardial Infarction Cardiac Nerve Remodeling and Cardiomyocyte Hypertrophy in Rats
por: Wang, Hui, et al.
Publicado: (2021)

Xist Exon 7 Contributes to the Stable Localization of Xist RNA on the Inactive X-Chromosome
por: Yamada, Norishige, et al.
Publicado: (2015)

Amlexanox and Forskolin Prevents Isoproterenol-Induced Cardiomyopathy by Subduing Cardiomyocyte Hypertrophy and Maladaptive Inflammatory Responses
por: Adzika, Gabriel Komla, et al.
Publicado: (2021)

Phosphocreatine Attenuates Isoproterenol-Induced Cardiac Fibrosis and Cardiomyocyte Apoptosis
por: Dai, Hui, et al.
Publicado: (2019)

Network Pharmacology of Yougui Pill Combined with Buzhong Yiqi Decoction for the Treatment of Sexual Dysfunction
por: Wang, Yangyun, et al.
Publicado: (2019)

Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ
por: Li, Hongming, et al.
Publicado: (2023)

Network pharmacology-based study to explore the mechanism of the Yiqi Gubiao pill in lung cancer treatment
por: Li, Zheng, et al.
Publicado: (2021)

Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
por: Cai, Lin, et al.
Publicado: (2017)

Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy
por: Yang, Ming-Hui, et al.
Publicado: (2020)

Xist RNA antagonizes the SWI/SNF chromatin remodeler BRG1 on the inactive X chromosome
por: Jégu, Teddy, et al.
Publicado: (2019)

Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson’s disease
por: Yu, Dingyi, et al.
Publicado: (2021)

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy
por: Gan, Mailin, et al.
Publicado: (2020)

Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration
por: Wang, ER, et al.
Publicado: (2014)

Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
por: Zhang, Yaxing, et al.
Publicado: (2016)

Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy
por: Errami, Mounir, et al.
Publicado: (2010)

Combinational effect of resveratrol and atorvastatin on isoproterenol-induced cardiac hypertrophy in rats
por: Chakraborty, Songjukta, et al.
Publicado: (2015)

Effect of α-Allocryptopine on Delayed Afterdepolarizations and Triggered Activities in Mice Cardiomyocytes Treated with Isoproterenol
por: Xu, Bin, et al.
Publicado: (2015)

AURKB-mediated effects on chromatin regulate binding versus release of XIST RNA to the inactive chromosome
por: Hall, Lisa L., et al.
Publicado: (2009)

Perturbed maintenance of transcriptional repression on the inactive X-chromosome in the mouse brain after Xist deletion
por: Adrianse, Robin L., et al.
Publicado: (2018)

Syringic acid mitigates isoproterenol‐induced cardiac hypertrophy and fibrosis by downregulating Ereg
por: Han, Xiongyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0hftk71797vbtu5fgrv7n8miov